Yonghao Yu

ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 18

Top Venues

Science advances

Nature synthesis

Biochemistry

Journal of proteome research

University of Texas Southwestern Medical Center

University of California Berkeley (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of Texas Southwestern Medical Center

United States

Assistant Professor :: Department of Biochemistry

Education History

University of California Berkeley

United States

PHD :: Department of Chemistry

Fudan University

China

BSC :: Department of Chemistry

Publications

Chiho Kim, Xu-Dong Wang, Zhengshuai Liu, Jianwei Hao, Shuai Wang, Peng Li, Zhenzhen Zi, Qing Ding, Seoyeon Jang, Jiwoong Kim, Yikai Luo, Kenneth E Huffman, Shreoshi Pal Choudhuri, Sofia Del Rio, Ling Cai, Han Liang, Benjamin J Drapkin, John D Minna, Yonghao Yu
Induced degradation of lineage-specific oncoproteins drives the therapeutic vulnerability of small cell lung cancer to PARP inhibitors. Science advances 10 (3) (2024)
Chiho Kim, Xu-Dong Wang, Zhengshuai Liu, Jianwei Hao, Shuai Wang, Peng Li, Zhenzhen Zi, Qing Ding, Seoyeon Jang, Jiwoong Kim, Yikai Luo, Kenneth E Huffman, Shreoshi Pal Choudhuri, Sofia Del Rio, Ling Cai, Han Liang, Benjamin J Drapkin, John D Minna, Yonghao Yu
Induced degradation of lineage-specific oncoproteins drives the therapeutic vulnerability of small cell lung cancer to PARP inhibitors. Science advances 10 (3) (2024)
Chiho Kim, Xu-Dong Wang, Zhengshuai Liu, Jianwei Hao, Shuai Wang, Peng Li, Zhenzhen Zi, Qing Ding, Seoyeon Jang, Jiwoong Kim, Yikai Luo, Kenneth E Huffman, Shreoshi Pal Choudhuri, Sofia Del Rio, Ling Cai, Han Liang, Benjamin J Drapkin, John D Minna, Yonghao Yu
Induced degradation of lineage-specific oncoproteins drives the therapeutic vulnerability of small cell lung cancer to PARP inhibitors. Science advances 10 (3) (2024)
Chiho Kim, Xu-Dong Wang, Zhengshuai Liu, Jianwei Hao, Shuai Wang, Peng Li, Zhenzhen Zi, Qing Ding, Seoyeon Jang, Jiwoong Kim, Yikai Luo, Kenneth E Huffman, Shreoshi Pal Choudhuri, Sofia Del Rio, Ling Cai, Han Liang, Benjamin J Drapkin, John D Minna, Yonghao Yu
Induced degradation of lineage-specific oncoproteins drives the therapeutic vulnerability of small cell lung cancer to PARP inhibitors. Science advances 10 (3) (2024)
Chiho Kim, Xu-Dong Wang, Zhengshuai Liu, Jianwei Hao, Shuai Wang, Peng Li, Zhenzhen Zi, Qing Ding, Seoyeon Jang, Jiwoong Kim, Yikai Luo, Kenneth E Huffman, Shreoshi Pal Choudhuri, Sofia Del Rio, Ling Cai, Han Liang, Benjamin J Drapkin, John D Minna, Yonghao Yu
Induced degradation of lineage-specific oncoproteins drives the therapeutic vulnerability of small cell lung cancer to PARP inhibitors. Science advances 10 (3) (2024)
Heping Deng, Hejun Deng, Chiho Kim, Peng Li, Xudong Wang, Yonghao Yu, Tian Qin
Synthesis of nimbolide and its analogues and their application as poly(ADP-ribose) polymerase-1 trapping inducers. Nature synthesis 3 (3) (2023)
Heping Deng, Hejun Deng, Chiho Kim, Peng Li, Xudong Wang, Yonghao Yu, Tian Qin
Synthesis of nimbolide and its analogues and their application as poly(ADP-ribose) polymerase-1 trapping inducers. Nature synthesis 3 (3) (2023)
Peng Li, Yuanli Zhen, Chiho Kim, Zhengshuai Liu, Jianwei Hao, Heping Deng, Hejun Deng, Min Zhou, Xu-Dong Wang, Tian Qin, Yonghao Yu
Nimbolide targets RNF114 to induce the trapping of PARP1 and synthetic lethality in BRCA -mutated cancer. Science advances 9 (43) (2023)
Heping Deng, Hejun Deng, Chiho Kim, Peng Li, Xudong Wang, Yonghao Yu, Tian Qin
Synthesis of nimbolide and its analogues and their application as poly(ADP-ribose) polymerase-1 trapping inducers. Nature synthesis 3 (3) (2023)
Zhenzhen Zi, Zhuzhen Zhang, Qiang Feng, Chiho Kim, Xu-Dong Wang, Jan-Bernd Funcke, Jinming Gao, Beth Levine, Yonghao Yu
Quantitative phosphoproteomic analyses identify STK11IP as a lysosome-specific substrate of mTORC1 that regulates lysosomal acidification. Nature communications 13 (1) (2022)
Qian Chen, Kai Ma, Xiuhua Liu, Shih-Hsun Chen, Peng Li, Yonghao Yu, Anthony K L Leung, Xiaochun Yu
Truncated PARP1 mediates ADP-ribosylation of RNA polymerase III for apoptosis. Cell discovery 8 (1) (2022)
Chiho Kim, Xu-Dong Wang, Zhengshuai Liu, Shan Zha, Yonghao Yu
Targeting Scaffolding Functions of Enzymes Using PROTAC Approaches. Biochemistry (2022)
Xu-Dong Wang, Chiho Kim, Yajie Zhang, Smita Rindhe, Melanie H Cobb, Yonghao Yu
Cholesterol Regulates the Tumor Adaptive Resistance to MAPK Pathway Inhibition. Journal of proteome research 20 (12) (2021)
Zhenzhen Zi, Yajie Zhang, Peng Zhang, Qing Ding, Michael Chu, Yiwen Chen, John D Minna, Yonghao Yu
A Proteomic Connectivity Map for Characterizing the Tumor Adaptive Response to Small Molecule Chemical Perturbagens. ACS chemical biology 15 (1) (2020)
Chiho Kim, Xu-Dong Wang, Yonghao Yu
PARP1 inhibitors trigger innate immunity via PARP1 trapping-induced DNA damage response. eLife 9 (2020)
Shuai Wang, Lei Han, Jungsoo Han, Peng Li, Qing Ding, Qing-Jun Zhang, Zhi-Ping Liu, Chuo Chen, Yonghao Yu
Uncoupling of PARP1 trapping and inhibition using selective PARP1 degradation. Nature chemical biology 15 (12) (2019)
Yuanli Zhen, Yonghao Yu
Proteomic Analysis of the Downstream Signaling Network of PARP1. Biochemistry 57 (4) (2018)
Yuanyuan Zhang, Yajie Zhang, Yonghao Yu
Global Phosphoproteomic Analysis of Insulin/Akt/mTORC1/S6K Signaling in Rat Hepatocytes. Journal of proteome research 16 (8) (2017)

Yonghao Yu.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Yonghao Yu